BioMedNewsBreaks

TuesdayMar 03, 2020 10:15 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Present at the Third Annual LD Micro Virtual Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that it will present at the third annual LD Micro Virtual Conference at 1:40 p.m. EST on Wednesday, March 4. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and answer questions from investors. “We are delighted to be hosting our third virtual event in order to showcase some of the truly unique names in micro-cap,” LD Micro President Chris Lahiji said in the news release. “There are many people and companies who are unable to…

Continue Reading

MondayMar 02, 2020 12:19 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Proposed Acquisition Further Positions it to Aid Efforts to Accelerate Discovery of New Anti-Cancers, Anti-Virals and Vaccines

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today provided an update on its proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine. According to the update, this move further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines. The acquisition will provide POAI with QM’s exclusively licensed, proven machine learning framework (“CoRE”), developed at CMU. CoRE, a predictive model-building platform for drug screening and optimization campaigns, uses hybrid machine learning…

Continue Reading

WednesdayFeb 26, 2020 12:21 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach

Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that leverages patient-derived xenografts (“PDx”). A recent article discussing the company reads, “Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By ‘fooling the tumor’ with an imitative environment, new drugs are able to be tested and potentially approved — all…

Continue Reading

FridayFeb 21, 2020 11:33 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Another Exemplary Addition to its Board

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that its Board of Directors has unanimously appointed Dan Handley, M.S., Ph.D., to the Board. According to the update, Dr. Handley serves as a professor and the director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences. Dr. Handley previously was the chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 non-profit corporation. “Predictive Oncology is once again very…

Continue Reading

ThursdayFeb 20, 2020 9:23 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $17,500,000 Common Stock Offering At-The-Market

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, on Wednesday announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of $3.50 each, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. There are no warrants in the offering. The company intends to use the proceeds from the offering, which are anticipated to be roughly $17,500,000 before deducting fees and other estimated offering expenses,…

Continue Reading

FridayFeb 14, 2020 2:26 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names New Member to Board of Directors

Predictive Oncology (NASDAQ: POAI) recently announced the appointment of Pam Prior, CPA, to the company’s Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee. An article further discussing the company reads, “Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller. As the founder and CEO of Priorities Group Inc., a provider of CFO services to small and mid-sized businesses, she has served as a CFO to a number of companies, including Gentris Corp., a private pharmacogenomics company…

Continue Reading

FridayFeb 14, 2020 9:00 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Inks Exclusive License Agreement with University of Pittsburgh for Diabetes Gene Therapy

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, recently announced its entry into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S., or 9% of the U.S. population. According to the update, Genprex’s licensed diabetes gene therapy technology is designed to reprogram alpha cells in the pancreas into beta-like cells, restoring their function, thereby replenishing insulin levels. “We are…

Continue Reading

TuesdayFeb 11, 2020 11:53 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh for Potentially Curative Gene Therapy Candidate for Diabetes

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, today announced its entry into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S., or 9% of the U.S. population. According to the update, Genprex’s licensed diabetes gene therapy technology is designed to reprogram alpha cells in the pancreas into beta-like cells, restoring their function, thereby replenishing insulin levels. “We are…

Continue Reading

ThursdayFeb 06, 2020 11:08 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Meets Nasdaq Minimum Bid Price Requirement, Regains Compliance

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its February 4, 2020 receipt of notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The Nasdaq Capital Market. Accordingly, the company has regained compliance with the Bid Price Rule and Nasdaq considers the matter closed. To view the full press release, visit http://nnw.fm/Fi5Dq About Genprex, Inc. Genprex, Inc. is…

Continue Reading

WednesdayFeb 05, 2020 1:37 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Focus Clinical Efforts on Oncoprex(TM) in Combination with Osimertinib for Treatment of Non-Small Cell Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provided a clinical update and focus for its Oncoprex(TM) immunogene therapy program for 2020. According to the update, Genprex will prioritize the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (“NSCLC”). Genprex, on January 14, 2020, received U.S Food and Drug Administration (“FDA”) Fast Track Designation for its Oncoprex immunogene therapy in combination with the EGFR tyrosine kinase inhibitor osimertinib (AstraZeneca’s Tagrisso(R), currently its highest grossing product) for the…

Continue Reading